Stockwatch: Like Moths To The Unvalidated Flame
Considering Target Validation In Light Of Novartis’s Lung Cancer Failure
Leaving the validation of a drug target until the end of Phase III studies is risky, but working on the unvalidated targets identified by others is riskier still.
You may also be interested in...
With approval timeline for OCA now thoroughly unclear and Genfit on the ropes, might the top spot in NASH end up with Galmed, AbbVie, Madrigal, Inventiva or Gilead instead?
The FDA’s rejection of Acadia’s label expansion into a broader patient population for its only approved drug resulted in an aggrieved reaction. Better disclosure from both sides would have helped.
Conventional wisdom from the first biosimilar launches was that the European market that was far tougher on innovator products than was the US. More recent data suggest that things may play out differently in the long run.